Clinical Scorecard: Are GLP-1s Linked to Optic Neuropathy?
At a Glance
| Category | Detail |
|---|---|
| Condition | Anterior Ischemic Optic Neuropathy |
| Key Mechanisms | Association with glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors. |
| Target Population | Patients with type 2 diabetes |
| Care Setting | Nationwide, register-based cohort study |
Key Highlights
- GLP-1 receptor agonists associated with a higher risk of anterior ischemic optic neuropathy compared to SGLT-2 inhibitors.
- Absolute risks at 1 year were 0.04% for GLP-1 and 0.02% for SGLT-2.
- At 5 years, risks were 0.12% for GLP-1 and 0.07% for SGLT-2.
- Differences in risk were reduced in patients receiving metformin.
- Residual confounding cannot be excluded.
Guideline-Based Recommendations
Diagnosis
- Anterior ischemic optic neuropathy identified through national patient register.
Management
- Consider diabetes severity and metformin use when evaluating risks.
Monitoring & Follow-up
- Monitor for signs of anterior ischemic optic neuropathy in patients using GLP-1 receptor agonists.
Risks
- Low absolute risks of anterior ischemic optic neuropathy in patients using GLP-1 receptor agonists.
Patient & Prescribing Data
Patients with type 2 diabetes initiating GLP-1 receptor agonists or SGLT-2 inhibitors.
Cautious interpretation of risk increase among GLP-1 users due to low absolute event rates.
Clinical Best Practices
- Assess individual patient risk factors when prescribing GLP-1 receptor agonists.
- Utilize propensity score weighting to balance demographic and clinical characteristics.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
